AMBRX BIOPHARMA INC.

10975 North Torrey Pines Road

La Jolla, CA 92037

March 31, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:	Ambrx Biopharma Inc.

Registration Statement on Form S-3 (File No. 333-271008)

Ladies and Gentlemen:

Reference is made to the Registration Statement on Form S-3 (File No. 333-271008) filed with the Securities and Exchange Commission (the “Commission”) by Ambrx Biopharma Inc. on March 30, 2023 (the “Registration Statement”). Pursuant to Rule 473(c) of the Securities Act of 1933, as amended (the “Act”), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated into the facing page of the Registration Statement:

“The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to said Section 8(a), may determine.”

Sincerely,

 

AMBRX BIOPHARMA INC.
By:		/s/ Sonja Nelson
Name: Sonja Nelson
Title: Chief Financial and Operating Officer

 

cc:	Carlos Ramirez, Cooley LLP